Lumefantrine-d9

Lumefantrine-d9 (CAS No.: 2477594-24-2) is the stable isotope-labeled counterpart of the antimalarial drug Lumefantrine. By introducing deuterium atoms into the molecular structure, it is mainly used in pharmacokinetic and metabolism studies in biomedical research. As part of artemisinin-based combination therapy (ACT), Lumefantrine is primarily used to treat malaria caused by Plasmodium falciparum. Its mechanism of action involves interfering with the parasite’s heme metabolism, leading to parasite death. In in vitro studies, Lumefantrine shows nanomolar to low micromolar inhibitory activity against Plasmodium. In cell and animal models, Lumefantrine-d9 can be used as an internal standard for drug metabolism and pharmacokinetic studies; the dose or concentration used in experiments typically depends on the experimental design and research objectives. With stable isotope labeling, researchers can more accurately track Lumefantrine’s metabolic pathways and kinetic characteristics in vivo. (biomart.cn)